Immix Biopharma Inc stock is traded at $7.20, with a volume of 1,416,893. It is down -9.66% in the last 24 hours and down -28.92% over the past month. Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Previous Close:
$7.97
Open:
$7.86
24h Volume:
1,416,893
Relative Volume:
1.14
Market Cap:
$596.90M
Revenue:
-
Net Income/Loss:
-$34.98M
P/E Ratio:
-
EPS:
-$0.9199
Net Cash Flow:
-$32.77M
1W Performance:
-9.77%
1M Performance:
-28.92%
6M Performance:
-24.69%
1Y Performance:
+136.07%
1-Day Range:
$7.12$7.95
1-Week Range:
$7.12$8.16
52-Week Range:
$2.85$15.10
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma IncSector
HealthcareIndustry
BiotechnologyPhone
(888) 958-1084Address
11400 WEST OLYMPIC BLVD., LOS ANGELES, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS